Synchron develops minimally invasive brain–computer interface (BCI) technologies designed to restore communication and device control for individuals with paralysis. The company’s flagship platform, the Stentrode, is an endovascular implant inserted via blood vessels, avoiding open-brain surgery. Its approach emphasizes safety, chronic use, and practical deployment for real-world BCI applications. Synchron positions its technology within regulated clinical and therapeutic care contexts.

The technology uses an array of electrodes mounted on a stent to record neural activity from cortical regions through the vasculature. Signals are decoded to infer user intent, enabling control of digital devices such as computers and communication interfaces. The endovascular design reduces surgical risk while allowing chronic, stable recordings. The platform supports adaptive decoding algorithms to optimize control accuracy over time.

Synchron targets individuals with severe motor impairments who require assistive technologies for communication and interaction. The Stentrode system is intended for use under professional clinical supervision and has been applied in early clinical trials. Its positioning reflects broader efforts to make high-performance BCIs more accessible through minimally invasive implantation strategies.